Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Knowledge and Practice Related to Compliance with Mass Drug Administration during the Egyptian National Filariasis Elimination Program

Identifieur interne : 003520 ( Main/Exploration ); précédent : 003519; suivant : 003521

Knowledge and Practice Related to Compliance with Mass Drug Administration during the Egyptian National Filariasis Elimination Program

Auteurs : Khaled M. Abd Elaziz ; Maged El-Setouhy ; Mark H. Bradley ; Reda M. R. Ramzy ; Gary J. Weil

Source :

RBID : PMC:3741246

Descripteurs français

English descriptors

Abstract

Lymphatic filariasis (LF) has been targeted for global elimination by 2020. The primary tool for the program is mass drug administration (MDA) with antifilarial medications to reduce the source of microfilariae required for mosquito transmission of the parasite. This strategy requires high MDA compliance rates. Egypt initiated a national filariasis elimination program in 2000 that targeted approximately 2.7 million persons in 181 disease-endemic localities. This study assessed factors associated with MDA compliance in year three of the Egyptian LF elimination program. 2,859 subjects were interviewed in six villages. The surveyed compliance rate for MDA in these villages was 85.3% (95% confidence interval = 83.9–86.5%). Compliance with MDA was positively associated with LF knowledge scores, male sex, and older age. Adverse events reported by 18.4% of participants were mild and more common in females. This study has provided new information on factors associated with MDA compliance during Egypt's successful LF elimination program.


Url:
DOI: 10.4269/ajtmh.12-0491
PubMed: 23751402
PubMed Central: 3741246


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Knowledge and Practice Related to Compliance with Mass Drug Administration during the Egyptian National Filariasis Elimination Program</title>
<author>
<name sortKey="Abd Elaziz, Khaled M" sort="Abd Elaziz, Khaled M" uniqKey="Abd Elaziz K" first="Khaled M." last="Abd Elaziz">Khaled M. Abd Elaziz</name>
</author>
<author>
<name sortKey="El Setouhy, Maged" sort="El Setouhy, Maged" uniqKey="El Setouhy M" first="Maged" last="El-Setouhy">Maged El-Setouhy</name>
</author>
<author>
<name sortKey="Bradley, Mark H" sort="Bradley, Mark H" uniqKey="Bradley M" first="Mark H." last="Bradley">Mark H. Bradley</name>
</author>
<author>
<name sortKey="Ramzy, Reda M R" sort="Ramzy, Reda M R" uniqKey="Ramzy R" first="Reda M. R." last="Ramzy">Reda M. R. Ramzy</name>
</author>
<author>
<name sortKey="Weil, Gary J" sort="Weil, Gary J" uniqKey="Weil G" first="Gary J." last="Weil">Gary J. Weil</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">23751402</idno>
<idno type="pmc">3741246</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741246</idno>
<idno type="RBID">PMC:3741246</idno>
<idno type="doi">10.4269/ajtmh.12-0491</idno>
<date when="2013">2013</date>
<idno type="wicri:Area/Pmc/Corpus">002C03</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002C03</idno>
<idno type="wicri:Area/Pmc/Curation">002C02</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002C02</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002238</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002238</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">001A91</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A91</idno>
<idno type="wicri:Area/PubMed/Curation">001A91</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A91</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001A91</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001A91</idno>
<idno type="wicri:Area/Ncbi/Merge">005A06</idno>
<idno type="wicri:Area/Ncbi/Curation">005A06</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">005A06</idno>
<idno type="wicri:doubleKey">0002-9637:2013:Abd Elaziz K:knowledge:and:practice</idno>
<idno type="wicri:Area/Main/Merge">003526</idno>
<idno type="wicri:Area/Main/Curation">003520</idno>
<idno type="wicri:Area/Main/Exploration">003520</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Knowledge and Practice Related to Compliance with Mass Drug Administration during the Egyptian National Filariasis Elimination Program</title>
<author>
<name sortKey="Abd Elaziz, Khaled M" sort="Abd Elaziz, Khaled M" uniqKey="Abd Elaziz K" first="Khaled M." last="Abd Elaziz">Khaled M. Abd Elaziz</name>
</author>
<author>
<name sortKey="El Setouhy, Maged" sort="El Setouhy, Maged" uniqKey="El Setouhy M" first="Maged" last="El-Setouhy">Maged El-Setouhy</name>
</author>
<author>
<name sortKey="Bradley, Mark H" sort="Bradley, Mark H" uniqKey="Bradley M" first="Mark H." last="Bradley">Mark H. Bradley</name>
</author>
<author>
<name sortKey="Ramzy, Reda M R" sort="Ramzy, Reda M R" uniqKey="Ramzy R" first="Reda M. R." last="Ramzy">Reda M. R. Ramzy</name>
</author>
<author>
<name sortKey="Weil, Gary J" sort="Weil, Gary J" uniqKey="Weil G" first="Gary J." last="Weil">Gary J. Weil</name>
</author>
</analytic>
<series>
<title level="j">The American Journal of Tropical Medicine and Hygiene</title>
<idno type="ISSN">0002-9637</idno>
<idno type="eISSN">1476-1645</idno>
<imprint>
<date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Albendazole (administration & dosage)</term>
<term>Albendazole (therapeutic use)</term>
<term>Animals</term>
<term>Diethylcarbamazine (administration & dosage)</term>
<term>Diethylcarbamazine (therapeutic use)</term>
<term>Egypt (epidemiology)</term>
<term>Elephantiasis, Filarial (drug therapy)</term>
<term>Elephantiasis, Filarial (epidemiology)</term>
<term>Elephantiasis, Filarial (prevention & control)</term>
<term>Elephantiasis, Filarial (psychology)</term>
<term>Female</term>
<term>Filaricides (administration & dosage)</term>
<term>Filaricides (therapeutic use)</term>
<term>Health Knowledge, Attitudes, Practice</term>
<term>Humans</term>
<term>Insecticide-Treated Bednets</term>
<term>Insecticides</term>
<term>Male</term>
<term>Medication Adherence (psychology)</term>
<term>Middle Aged</term>
<term>Mosquito Control (methods)</term>
<term>Sex Factors</term>
<term>Surveys and Questionnaires</term>
<term>Wuchereria bancrofti</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Albendazole (administration et posologie)</term>
<term>Albendazole (usage thérapeutique)</term>
<term>Animaux</term>
<term>Connaissances, attitudes et pratiques en santé</term>
<term>Diéthylcarbamazine (administration et posologie)</term>
<term>Diéthylcarbamazine (usage thérapeutique)</term>
<term>Enquêtes et questionnaires</term>
<term>Facteurs sexuels</term>
<term>Femelle</term>
<term>Filaricides (administration et posologie)</term>
<term>Filaricides (usage thérapeutique)</term>
<term>Filariose lymphatique ()</term>
<term>Filariose lymphatique (psychologie)</term>
<term>Filariose lymphatique (traitement médicamenteux)</term>
<term>Filariose lymphatique (épidémiologie)</term>
<term>Humains</term>
<term>Insecticides</term>
<term>Jeune adulte</term>
<term>Lutte contre les moustiques ()</term>
<term>Moustiquaires de lit traitées aux insecticides</term>
<term>Mâle</term>
<term>Observance du traitement médicamenteux (psychologie)</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Wuchereria bancrofti</term>
<term>Égypte (épidémiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Albendazole</term>
<term>Diethylcarbamazine</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Albendazole</term>
<term>Diethylcarbamazine</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en">
<term>Egypt</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Albendazole</term>
<term>Diéthylcarbamazine</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en">
<term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Mosquito Control</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="psychologie" xml:lang="fr">
<term>Filariose lymphatique</term>
<term>Observance du traitement médicamenteux</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en">
<term>Elephantiasis, Filarial</term>
<term>Medication Adherence</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Filariose lymphatique</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Albendazole</term>
<term>Diéthylcarbamazine</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr">
<term>Filariose lymphatique</term>
<term>Égypte</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Animals</term>
<term>Female</term>
<term>Health Knowledge, Attitudes, Practice</term>
<term>Humans</term>
<term>Insecticide-Treated Bednets</term>
<term>Insecticides</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Sex Factors</term>
<term>Surveys and Questionnaires</term>
<term>Wuchereria bancrofti</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Animaux</term>
<term>Connaissances, attitudes et pratiques en santé</term>
<term>Enquêtes et questionnaires</term>
<term>Facteurs sexuels</term>
<term>Femelle</term>
<term>Filariose lymphatique</term>
<term>Humains</term>
<term>Insecticides</term>
<term>Jeune adulte</term>
<term>Lutte contre les moustiques</term>
<term>Moustiquaires de lit traitées aux insecticides</term>
<term>Mâle</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Wuchereria bancrofti</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr">
<term>Égypte</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>Lymphatic filariasis (LF) has been targeted for global elimination by 2020. The primary tool for the program is mass drug administration (MDA) with antifilarial medications to reduce the source of microfilariae required for mosquito transmission of the parasite. This strategy requires high MDA compliance rates. Egypt initiated a national filariasis elimination program in 2000 that targeted approximately 2.7 million persons in 181 disease-endemic localities. This study assessed factors associated with MDA compliance in year three of the Egyptian LF elimination program. 2,859 subjects were interviewed in six villages. The surveyed compliance rate for MDA in these villages was 85.3% (95% confidence interval = 83.9–86.5%). Compliance with MDA was positively associated with LF knowledge scores, male sex, and older age. Adverse events reported by 18.4% of participants were mild and more common in females. This study has provided new information on factors associated with MDA compliance during Egypt's successful LF elimination program.</p>
</div>
</front>
</TEI>
<affiliations>
<list></list>
<tree>
<noCountry>
<name sortKey="Abd Elaziz, Khaled M" sort="Abd Elaziz, Khaled M" uniqKey="Abd Elaziz K" first="Khaled M." last="Abd Elaziz">Khaled M. Abd Elaziz</name>
<name sortKey="Bradley, Mark H" sort="Bradley, Mark H" uniqKey="Bradley M" first="Mark H." last="Bradley">Mark H. Bradley</name>
<name sortKey="El Setouhy, Maged" sort="El Setouhy, Maged" uniqKey="El Setouhy M" first="Maged" last="El-Setouhy">Maged El-Setouhy</name>
<name sortKey="Ramzy, Reda M R" sort="Ramzy, Reda M R" uniqKey="Ramzy R" first="Reda M. R." last="Ramzy">Reda M. R. Ramzy</name>
<name sortKey="Weil, Gary J" sort="Weil, Gary J" uniqKey="Weil G" first="Gary J." last="Weil">Gary J. Weil</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003520 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003520 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:3741246
   |texte=   Knowledge and Practice Related to Compliance with Mass Drug Administration during the Egyptian National Filariasis Elimination Program
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23751402" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1 

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024